RAYZEBIO
Live / Allowed — Published for opposition (as of 14 Sept 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 17 Mar 2026 filing date already counts against anyone who files later.
Record
- Serial number
- 99707887
- Mark type
- Word mark
- Filed
- 17 Mar 2026
- Published for opposition
- 21 Jul 2026
- Attorney of record
- Xiomara F. Triana
Goods and services
- Class 005 — Pharmaceuticals: Radiopharmaceutical preparations for the treatment of cancer and solid tumors.; Diagnostic radiopharmaceutical preparations; Radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; Diagnostic agents for medical purposes; Radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for the treatment and prevention of cancer
Owner
- RayzeBio, Inc., San Diego, CA, US
- RayzeBio, Inc., San Diego, CA, US
Board proceedings on this mark
- Extension of Time to Oppose No. 99707887 — Glaxo Group Limited v. RayzeBio, Inc., filed 14 Aug 2026 (Terminated)
Prosecution history
- 14 Sept 2026 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 11 Sept 2026 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 14 Aug 2026 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 21 Jul 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 21 Jul 2026 — PUBLISHED FOR OPPOSITION
- 15 Jul 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Jun 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Jun 2026 — ASSIGNED TO EXAMINER
- 17 Mar 2026 — APPLICATION FILING RECEIPT MAILED
- 17 Mar 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 17 Mar 2026 — NEW APPLICATION ENTERED